RBx11160 |
Clinical Development of a new peroxide anti-malarial agent (RBx11160)
On behalf of MMV and Ranbaxy Laboratories Ltd. the Pharmaceutical Medicine Unit was responsible for the coordination of this Phase IIa trial at 4 sites in India, Thailand, Tanzania and Zanzibar. Our role comprised the provision of scientific advice, procurement of equipment, study initiation and monitoring (African sites), and technical support to the study centres.
